Resources/References

References

  1. Anie KA Green J: Psychological therapies for sickle cell disease and pain. Cochrane Database Syst Rev (2):CD001916. doi 2:CD001916, 2012
  2. Association of Pediatric Anesthetists of Great Britain and Ireland: Good practice in postoperative and procedural pain management, 2nd edition. Pediatr Anesth 22 Suppl 1 :1-79, 2012
  3. Ataga KI, Kutlar A Kanter J: Crizanlizumab in Sickle Cell Disease. N Engl J Med 376 18:1796, 2017
  4. Ataga KI, Kutlar A, Kanter J, Liles D, Cancado R, Friedrisch J, Guthrie TH, Knight-Madden J, Alvarez OA, Gordeuk VR, Gualandro S, Colella MP, Smith WR, Rollins SA, Stocker JW Rother RP: Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease. N Engl J Med 376 5:429-439, 2017
  5. Brandow AM, Brousseau DC, Pajewski NM Panepinto JA: Vaso-occlusive painful events in sickle cell disease: impact on child well-being. Pediatr Blood Cancer 54 1:92-97, 2010
  6. Dampier C, Ely E, Eggleston B, Brodecki D O'Neal P: Physical and cognitive-behavioral activities used in the home management of sickle pain: a daily diary study in children and adolescents. Pediatr Blood Cancer 43 6:674-678, 2004
  7. Dampier C, Lieff S, LeBeau P, Rhee S, McMurray M, Rogers Z, Smith-Whitley K, Wang W Comprehensive Sickle Cell Centers (CSCC) Clinical Trial Consortium (CTC): Health-related quality of life in children with sickle cell disease: a report from the Comprehensive Sickle Cell Centers Clinical Trial Consortium. Pediatr Blood Cancer 55 3:485-494, 2010
  8. Edwards LY Edwards CL: Psychosocial treatments in pain management of sickle cell disease. J Natl Med Assoc 102 11:1084-1094, 2010
  9. Ellison A, Payne L, Norris C, Smith-Whitley K, Jacobstein C Lavelle J: ED Pathway for Evaluation/Treatment of Children with Sickle Cell Disease and Pain. Available at: http://www.chop.edu/pathways/emergency-department/sickle-cell-disease-p… Accessed March 1, 2019
  10. Ely B, Dampier C, Gilday M, O'Neal P Brodecki D: Caregiver report of pain in infants and toddlers with sickle cell disease: reliability and validity of a daily diary. J Pain 3 1:50-57, 2002
  11. FDA restricts use of prescription codeine pain and cough medicines and tramadol pain medicines in children; recommends against use in breastfeeding women. Available at: https://www.fda.gov/media/104268/download Accessed May 1, 2019
  12. Hagedorn JM Monico EC: Ketamine Infusion for Pain Control in Acute Pediatric Sickle Cell Painful Crises. Pediatr Emerg Care 35 1:78-79, 2019
  13. Hinz B, Cheremina O Brune K: Acetaminophen (paracetamol) is a selective cyclooxygenase-2 inhibitor in man. FASEB J 22 2:383-390, 2008
  14. Hogestatt ED, Jonsson BA, Ermund A, Andersson DA, Bjork H, Alexander JP, Cravatt BF, Basbaum AI Zygmunt PM: Conversion of acetaminophen to the bioactive N-acylphenolamine AM404 via fatty acid amide hydrolase-dependent arachidonic acid conjugation in the nervous system. J Biol Chem 280 36:31405-31412, 2005
  15. Institute of Medicine (US) Committee on Understanding and Eliminating Racial and Ethnic Disparities in Health Care: , 2003 The Story of Sickle Cell Disease Related Pain: References 2
  16. Isakson P, Hubbard R: Analgesics: Nonsteroidal Anti-Inflammatory Drugs, in Anonymous: Anesthetic Pharmacology: Physiologic Principles and Clinical Practice. Philadelphia, PA, Churchill Livingstone, 2004
  17. Jennings CA, Bobb BT, Noreika DM Coyne PJ: Oral ketamine for sickle cell crisis pain refractory to opioids. J Pain Palliat Care Pharmacother 27 2:150-154, 2013
  18. Kanter J Kruse-Jarres R: Management of sickle cell disease from childhood through adulthood. Blood Rev 27 6:279-287, 2013
  19. Konotey-Ahulu FI: The sickle cell diseases. Clinical manifestations including the "sickle crisis". Arch Intern Med 133 4:611-619, 1974
  20. Kotila TR, Busari OE, Makanjuola V Eyelade OR: Addiction Or Pseudoaddiction in Sickle Cell Disease Patients: Time to Decide - a Case Series. Ann Ib Postgrad Med 13 1:44-47, 2015
  21. Manwani D Frenette PS: Vaso-occlusion in sickle cell disease: pathophysiology and novel targeted therapies. Blood 122 24:3892-3898, 2013
  22. Neri CM, Pestieau SR Darbari DS: Low-dose ketamine as a potential adjuvant therapy for painful vasoocclusive crises in sickle cell disease. Paediatr Anaesth 23 8:684-689, 2013
  23. Niihara Y, Miller ST, Kanter J, Lanzkron S, Smith WR, Hsu LL, Gordeuk VR, Viswanathan K, Sarnaik S, Osunkwo I, Guillaume E, Sadanandan S, Sieger L, Lasky JL, Panosyan EH, Blake OA, New TN, Bellevue R, Tran LT, Razon RL, Stark CW, Neumayr LD, Vichinsky EP Investigators of the Phase 3 Trial of lGlutamine in Sickle Cell Disease: A Phase 3 Trial of l-Glutamine in Sickle Cell Disease. N Engl J Med 379 3:226-235, 2018
  24. Opioid crisis adds to pain of sickle cell patients. Available  at:https://www.nhlbi.nih.gov/news/2017/opioid-crisis-adds-pain-sickle-cell… Accessed May 15, 2019
  25. Oucher! Available at: http://www.oucher.org/differences.html Accessed March 1, 2019
  26. Pack-Mabien A Haynes J,Jr: A primary care provider's guide to preventive and acute care management of adults and children with sickle cell disease. J Am Acad Nurse Pract 21 5:250-257, 2009
  27. Puri L, Nottage KA, Hankins JS Anghelescu DL: State of the Art Management of Acute Vaso-occlusive Pain in Sickle Cell Disease. Paediatr Drugs 20 1:29-42, 2018
  28. Ruta NS Ballas SK: The Opioid Drug Epidemic and Sickle Cell Disease: Guilt by Association. Pain Med 17 10:1793-1798, 2016
  29. Sheehy KA, Finkel JC, Darbari DS, Guerrera MF Quezado ZM: Dexmedetomidine as an Adjuvant to Analgesic Strategy During Vaso-Occlusive Episodes in Adolescents with Sickle-Cell Disease. Pain Pract 15 8:E90-7, 2015
  30. Sheehy KA, Muller EA, Lippold C, Nouraie M, Finkel JC Quezado ZM: Subanesthetic ketamine infusions for the treatment of children and adolescents with chronic pain: a longitudinal study. BMC Pediatr 15:198-015-0515-4, 2015
  31. Sibinga EM, Shindell DL, Casella JF, Duggan AK Wilson MH: Pediatric patients with sickle cell disease: use of complementary and alternative therapies. J Altern Complement Med 12 3:291-298, 2006 The Story of Sickle Cell Disease Related Pain: References 3
  32. Sickle Cell Disease Topoics. Available at: http://www.nhlbi.nih.gov/health/health-topics/topics/sca/ Accessed February 20, 2019
  33. Sickle cell disease. Available at: http://ghr.nlm.nih.gov/condition/sickle-cell-disease Accessed February 20, 2019
  34. Smith K, Reinman L, Schatz J Roberts CW: Parent Perspectives on Pain Management in Preschool-Age Children With Sickle Cell Disease. J Pediatr Oncol Nurs 35 1:16-24, 2018
  35. Stuart MJ Nagel RL: Sickle-cell disease. Lancet 364 9442:1343-1360, 2004
  36. The Cycle of Vaso-Occlusion and VOCs. Available at: https://www.rethinkscd.com/vaso-occlusionvocs/#ongoing-vaso-occlusion-c… Accessed February 20, 2019
  37. West DC, Romano PS, Azari R, Rudominer A, Holman M Sandhu S: Impact of environmental tobacco smoke on children with sickle cell disease. Arch Pediatr Adolesc Med 157 12:1197-1201, 2003
  38. Wren AA, Ross AC, D'Souza G, Almgren C, Feinstein A, Marshall A Golianu B: Multidisciplinary Pain Management for Pediatric Patients with Acute and Chronic Pain: A Foundational Treatment Approach When Prescribing Opioids. Children (Basel) 6 2:10.3390/children6020033, 2019
  39. Wright J Ahmedzai SH: The management of painful crisis in sickle cell disease. Curr Opin Support Palliat Care 4 2:97-106, 2010
  40. Wong-Baker FACES Pain Rating Scale . Available at: https://wongbakerfaces.org/ Accessed March 1, 2019
  41. Yaster M: Multimodal analgesia in children. Eur J Anaesthesiol 27 10:851-857, 2010
  42. Young JR, Sawe HR, Mfinanga JA, Nshom E, Helm E, Moore CG, Runyon MS Reynolds SL: Subdissociative intranasal ketamine plus standard pain therapy versus standard pain therapy in the treatment of paediatric sickle cell disease vaso-occlusive crises in resource-limited settings: study protocol for a randomised controlled trial. BMJ Open 7 7:e017190-2017-017190, 2017
SUPPORTING ORGANIZATIONS
University of Pennsylvania logo
University of Pennsylvania